AZD-2287

N/A

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NameAZD-2287
Drug Alias NameAZD2287
ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agent
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A